Nitrous Oxide for Obsessive-Compulsive Disorder
Trial Summary
What is the purpose of this trial?
This trial uses nitrous oxide gas, commonly known as laughing gas, to see if it can quickly help people with OCD. It targets individuals with OCD because they often struggle with persistent and distressing thoughts and behaviors. The gas might work by altering brain chemicals to improve mood and reduce symptoms.
Will I have to stop taking my current medications?
The trial does not specify if you must stop taking your current medications, but it mentions that you need to tolerate a treatment-free period and cannot use medications that might increase risk. It's best to discuss your specific medications with the trial team.
Is nitrous oxide safe for human use?
How is nitrous oxide different from other drugs for OCD?
Nitrous oxide is unique because it is an inhaled gas traditionally used for anesthesia, and it may offer a novel approach for treating OCD by potentially affecting brain chemistry differently than standard medications. Unlike typical OCD treatments, which are often pills or therapy, nitrous oxide is administered through inhalation, providing a different experience and possibly faster effects.26789
Research Team
Peter J van Roessel, MD, PhD
Principal Investigator
Stanford Univeristy
Eligibility Criteria
This trial is for adults aged 18-65 with a primary diagnosis of OCD who have severe symptoms. Participants must be able to give informed consent and go through a treatment-free period. It's not open to those on conflicting medications, with certain psychiatric or medical conditions, or women who are pregnant or nursing.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive a single inhalation of either nitrous oxide or nitrogen for 60 minutes
Follow-up
Participants are monitored for improvement in OCD symptoms using the YBOCS scale
Treatment Details
Interventions
- Nitrous Oxide (Inhaled Anesthetic)
Nitrous Oxide is already approved in Canada for the following indications:
- Anesthesia
- Pain relief
- Hypoxic respiratory failure in neonates
Find a Clinic Near You
Who Is Running the Clinical Trial?
Stanford University
Lead Sponsor
Dr. Richard A. Miller
Stanford University
Chief Executive Officer since 2023
Stanford University, MD
Dr. Robert Schott
Stanford University
Chief Medical Officer since 2021
University of Michigan, MD
Brain & Behavior Research Foundation
Collaborator
Dr. Jeffrey Borenstein
Brain & Behavior Research Foundation
Chief Executive Officer since 2018
MD from New York University, undergraduate degree from Harvard
Dr. Herbert Pardes
Brain & Behavior Research Foundation
Chief Medical Officer since 2017
MD from Harvard Medical School